FimmCyte AG, a pioneering Swiss biotech developing targeted immunotherapies for chronic fibro-inflammatory diseases, announces a strategic research collaboration and option-to-license agreement with Gedeon Richter Plc., a leading pharmaceutical company in women’s health, headquartered in Hungary, operating Central Europe's largest R&D hub.
Under the collaboration, FimmCyte and Gedeon Richter will conduct joint research and development activities to accelerate FMC2 path towards the clinic and ultimately to patients. Gedeon Richter will have global exclusive rights if they decide to exercise their exclusive option prior to initiation of the first-in-human clinical study.
FimmCyte believes FMC2 has the potential to be one of the first disease-modifying treatments for endometriosis, designed to address the root cause of endometriosis. FMC2 is a first-in-class molecule based on FimmCyte’s proprietary antibody platform that is designed to lead to durable clinical management of chronic fibro-inflammatory diseases such as endometriosis.
VISCHER advised FimmCyte on all Swiss legal issues related to the partnership. The VISCHER team was led by Luzius Zumstein (Managing Associate, Life Sciences) with Christian Wyss (Partner, Life Sciences).
Author: Christian Wyss
